Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma

Nanoformulation of Talazoparib Increases Maximum Tolerated Doses in Combination With Temozolomide for Treatment of Ewing Sarcoma

The Pediatric Preclinical Testing Program previously identified the PARP inhibitor talazoparib (TLZ) as a means to potentiate temozolomide (TMZ) activity for the treatment of Ewing sarcoma. However, the combination of TLZ and TMZ has been toxic in both preclinical and clinical testing, necessitating...

Full description

Bibliographic Details
Main Authors: Paige Baldwin, Rostislav Likhotvorik, Nabeela Baig, Jodie Cropper, Ruth Carlson, Raushan Kurmasheva, Srinivas Sridhar
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-12-01
Series:Frontiers in Oncology
Subjects:
talazoparib
temozolomide
nanoparticle
combination therapy
Ewing sarcoma
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2019.01416/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2019.01416/full

Similar Items